Welcome to our dedicated page for OKYO Pharma SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma Limited reports that its Chief Development Officer and Director, Gary Jacob, has acquired 30,980 ordinary shares on Nasdaq at $1.59 per share, increasing his holding to 108,920 shares. The company highlights its lead candidate urcosimod, which has shown anti-inflammatory and pain‑reducing effects in preclinical models and positive pain‑reduction data in an 18‑subject Phase 2a neuropathic corneal pain trial and a prior 240‑subject dry eye disease trial. OKYO recently completed a successful Phase 2 trial in neuropathic corneal pain and plans a ~150‑subject Phase 2b/3 multiple‑dose study in the first half of this year.
OKYO Pharma Ltd Chief Development Officer Gary S. Jacob filed an initial ownership report showing he holds 108,920 shares of common stock directly. He also reports multiple option awards over common stock with exercise prices ranging from 1.46 to 2.75 per share and expirations between 2033 and 2035.
OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone has filed an initial ownership report on Form 3. The filing shows that he directly holds 10,526,416 shares of common stock of OKYO Pharma Ltd following the reported position, establishing his status as a significant shareholder.
OKYO Pharma reported new exploratory Phase 2 data for its investigational eye therapy urcosimod 0.05% in neuropathic corneal pain (NCP). In a 12-week randomized, double-masked, placebo-controlled study, patients receiving urcosimod (n=6) showed greater improvements in several patient-reported quality-of-life measures versus placebo (n=6).
On a 0–10 scale, mean change in enjoying life/relationships was −4.5 for urcosimod compared with 0 for placebo, mood improved by −1.5 versus −0.5, and time spent thinking about eye pain fell by −3.0 versus −1.5. These outcomes build on previously reported Visual Analogue Scale pain reductions and suggest broader emotional and functional benefits.
The new data will be presented at the ARVO 2026 Annual Meeting and support OKYO’s plan for larger confirmatory development, including a multi-center Phase 2b/3 trial in NCP, a debilitating condition with no FDA-approved therapies.
OKYO Pharma Limited reports that the underwriter has partially exercised its option to buy extra shares from the company in a recent equity offering. Piper Sandler & Co. purchased an additional 1,109,060 ordinary shares on March 12, 2026, lifting total gross proceeds from the underwritten public offering to approximately $22 million before fees and expenses. This follows the initial sale of 10,815,000 ordinary shares at $1.85 per share, all issued by the company under an effective Form F-3 shelf registration.
OKYO Pharma Limited filed a Form 6-K highlighting that its abstract on urcosimod for neuropathic corneal pain (NCP) was accepted for presentation at the ARVO 2026 Annual Meeting in Denver. Chief Scientific Officer Raj Patil, Ph.D., will present first-in-human data showing clinically meaningful pain reduction on the Visual Analogue Scale and improved quality-of-life metrics in NCP patients.
The Phase 2a proof-of-concept trial of urcosimod, a novel non-opioid, preservative-free eye drop with dual pain-relieving and anti-inflammatory activity, also suggested potential restoration of corneal nerve structure. Urcosimod holds FDA Fast Track designation and the first IND clearance specifically for NCP, and OKYO plans to initiate an approximately 150-patient multicenter Phase 2b/3 study in the first half of this year.
OKYO Pharma Ltd reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen jointly beneficially own 4,058,445 Ordinary Shares, representing 7.9% of the class as of February 17, 2026.
The shares are held by Point72 Associates, LLC and the filing states Point72 Asset Management has shared voting and shared dispositive power over these 4,058,445 shares. The statement is submitted under a Joint Filing Agreement and lists the reporting parties' principal business address in Stamford, Connecticut.
OKYO Pharma Limited is offering 10,815,000 ordinary shares at $1.85 per share, raising about $20.0 million before underwriting fees. An additional 1,622,250 shares may be sold if the underwriters exercise their 30‑day option in full.
OKYO expects net proceeds of approximately $18.5 million, which it plans to use for clinical development of its product candidates, general corporate purposes and working capital. Shares outstanding will rise to 51,370,197 (or 52,992,447 if the option is fully exercised), creating immediate dilution of $1.54 per share compared with an as adjusted net tangible book value of $0.31.
The company is an emerging growth, clinical‑stage ophthalmology biotech focused on urcosimod for neuropathic corneal pain and dry eye disease. Its ordinary shares trade on the Nasdaq Capital Market under the symbol “OKYO,” and the offering is underwritten on a firm commitment basis by Piper Sandler.
OKYO Pharma Ltd disclosed that investor Jorey Chernett has filed Amendment No. 2 to a Schedule 13G reporting a significant stake in the company’s common shares. Chernett beneficially owns 3,802,194 shares, representing 9.45% of the outstanding common stock as of the event date.
The filing states that Chernett has sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive authority. It also certifies that the securities were not acquired to change or influence control of OKYO Pharma Ltd, but rather as a passive investment.
OKYO Pharma Limited entered an underwriting agreement with Piper Sandler for an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share. The underwriter has a 30-day option to buy up to 1,622,250 additional shares at the same public price, less fees. Gross proceeds are expected to be approximately $20 million before discounts, commissions and expenses, with all shares sold by the company. Closing is expected on February 17, 2026, subject to customary conditions. OKYO plans to use net proceeds for clinical development of its product candidates, general corporate purposes and working capital. The deal is made under an effective Form F-3 registration, and an updated investor presentation is furnished to investors.